文章摘要
蒙药那如-3味丸对普瑞巴林联合神经阻滞治疗神经病理性疼痛效果的影响
Effect of Mongolian medicine Naru-3 pills on the treatment of neuropathic pain with pregabalin combined with nerve block
  
DOI：10.12089/jca.2024.10.011
中文关键词: 蒙药那如-3味丸  神经病理性疼痛  疼痛评分  睡眠质量  炎性因子
英文关键词: Mongolian Naru-3 pills  Neuropathic pain  Pain scores  Sleep quality  Inflammatory factors
基金项目:高等学校青年科技英才支持计划（NJYT22020）；内蒙古自治区卫生健康科技计划项目（202201244）；内蒙古医科大学蒙药学“一流学科”引进培育人才科研项目（ylxkyjrc2021-02）
作者单位E-mail
越娜 017000,鄂尔多斯市中心医院康巴什部麻醉科  
澈力木格 内蒙古医科大学民族医药创新中心  
李辉 内蒙古医科大学附属医院麻醉科  
吕亮亮 内蒙古医科大学附属医院疼痛科  
郎海云 内蒙古医科大学附属医院疼痛科  
铁植 内蒙古医科大学附属医院麻醉科  
都义日 内蒙古医科大学附属医院麻醉科 duyiri10520@sina.com 
摘要点击次数: 851
全文下载次数: 431
中文摘要:
      
目的：探究蒙药那如-3味丸对普瑞巴林联合神经阻滞治疗神经病理性疼痛（NP）效果的影响。
方法：选择2022年10月至2023年9月确诊为NP的疼痛科住院患者41例，男20例，女21例，年龄40～80岁，BMI≥18.5 kg/m2。采用随机数字表法将患者分为两组：蒙药那如-3味丸组（观察组，n=20）和常规治疗组（对照组，n=21）。对照组为常规治疗，口服普瑞巴林胶囊联合超声引导下疼痛区域神经阻滞；观察组在常规治疗的基础上增加蒙药那如-3味丸（2 g/10粒），每晚临睡前口服3~5粒，共2周。记录治疗前1 d、治疗后2周、1个月、2个月数字评分量表（NRS）疼痛评分、简化McGill疼痛问卷（SF-MPQ）评分、匹兹堡睡眠质量指数（PSQI）。分别于治疗前1 d、治疗后2周采用ELISA法检测血清IL-6、IL-8、IL-1β、TNF-α浓度。记录治疗期间不良反应的发生情况，如恶心、呕吐、腹胀、心悸、嗜睡和头晕等。
结果：与治疗前1 d比较，治疗后2周、1个月、2个月两组NRS疼痛评分、SF-MPQ评分、PSQI均明显降低（P＜0.05）；治疗后2周两组血清IL-6、IL-1β、TNF-α浓度明显降低（P＜0.05）。与对照组比较，治疗后2周、1个月、2个月观察组NRS疼痛评分、SF-MPQ评分、PSQI均明显降低（P＜0.05）；治疗后2周观察组IL-6、IL-1β、TNF-α浓度明显降低（P＜0.05）。两组不良反应发生率差异无统计学意义。
结论：蒙药那如-3味丸联合常规疗法可有效减轻NP患者的疼痛，改善患者的睡眠质量，且可能具有调节神经炎症作用。
英文摘要:
      
Objective: To explore the effect of Mongolian medicine Naru-3 pills on the treatment of neuropathic pain (NP) with pregabalin combined with nerve block.
Methods: Forty-one hospitalized patients in the department of pain medicine diagnosed with NP from October 2022 to September 2023 were selected, including 20 males and 21 females, aged 40-80 years, BMI ≥ 18.5 kg/m2. The patients were divided into two groups by random number table method: Mongolian medicine Naru-3 pills group (observation group, n = 20) and conventional treatment group (control group, n = 21). The control group received conventional treatment: oral pregabalin capsule combined with ultrasound-guided nerve block in pain area. The observation group was added oral administration of Mongolian medicine Naru-3 pills (2 g/10 capsules) on the basis of conventional treatment, taking 3-5 capsules orally before going to bed every night for 2 weeks. The numerical rating scale (NRS) pain score, short-form McGill pain questionnaire (SF-MPQ) score, and Pittsburgh sleep quality index (PSQI) were recorded before treatment and 2 weeks, 1 month, and 2 months after the treatment. The serum concentrations of IL-6, IL-8, IL-1β, and TNF-α were detected by enzyme-linked immunosorbent assay (ELISA) 1 day before treatment and 2 weeks after treatment. Occurrence of adverse reactions during treatment such as nausea, vomiting, bloating, palpitations, drowsiness, and dizziness were recorded.
Results: Compared with 1 day before treatment, NRS pain score, SF-MPQ score, and PSQI were lower in both groups 2 weeks, 1 month, and 2 months after the treatment (P < 0.05), the serum concentrations of IL-6, IL-1β, and TNF-α were reduced in both groups 2 weeks after the treatment (P < 0.05). Compared with the control group, NRS pain score, SF-MPQ score, and PSQI were lower in the observation group 2 weeks, 1 month, and 2 months after the treatment (P < 0.05); the serum concentrations of IL-6, IL-1β, and TNF-α were reduced in the observation group 2 weeks after the treatment (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups.
Conclusion: Mongolian Naru-3 pills combined with conventional therapy can effectively reduce the pain of NP patients, improve the quality of sleep of patients, and may have the effect of regulating neuroinflammation.
查看全文   查看/发表评论  下载PDF阅读器
关闭